Clinical Trial Update: A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis [Phase 1]

View source ↗

Summary

Phase 1 single-dose pediatric study in 2 to <18-year-olds with secondary hyperparathyroidism on haemodialysis (completed; results posted 2019-07-10).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Snippet

Sponsor: Amgen | Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Status: COMPLETED | Results posted: 2019-07-10